All In Biotech

NDA 211225 · Novartis

Zykadia

Ceritinib · Oral · Kinase Inhibitor

Orphan

Last checked: Nov 20, 2026Latest source record: Oct 7, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 18, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

49

3 Phase 3, 6 recruiting

FAERS reports

2,384

1,941 serious, 553 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 28, 2026.

ZYKADIA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1)] . ZYKADIA is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )

Mechanism: Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitro and in vivo assays. Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZYKADIA · CERITINIB 150MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ceritinib" as an intervention, any sponsor and status, largest first.

All 49 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression430
  • diarrhoea427
  • nausea343
  • death281
  • vomiting224
  • metastases to central nervous system172
  • fatigue134
  • non-small cell lung cancer130
  • decreased appetite119
  • disease progression112
  • dyspnoea102
  • abdominal pain100

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
201498
2015332
2016371
2017311
2018312
2019182
2020182
2021221
2022183
202391
202453
202529
202617

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zykadia (Ceritinib)

2024 spending

$4.6M

Beneficiaries

61

424 claims

Per beneficiary

$74,619

$147.11 per unit

View as table
YearSpending
2020$5,105,689
2021$4,142,424
2022$3,999,309
2023$4,498,924
2024$4,551,745

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 74 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.